Mira Pharmaceuticals opened lower at $0.62, compared with its previous close of $0.62. In the last trading session, the stock traded between $0.62 and $0.65. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Mira Pharmaceuticals is now worth
$ 8.75
Resulting in a loss of
$ 91.25 (91.25%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.03 (+4.32%)
Day High
$0.65
Day Low
$0.62
Day Open
$0.62
Prev Close
$0.62
Volume
62,035
1W Return
16.73%
1M Return
-6.48%
3M Return
-16.69%
6M Return
-34.44%
1Y Return
-55.24%
Fundamentals
Market Cap ($ Mn)
27
PE Ratio
-
PB Ratio
3.86
PEG Ratio
-
ROE
-237.28%
ROCE
-239.53%
EPS (TTM)
$-0.03
Investment Returns
1 Week
16.73%
1 Month
-6.48%
3 Months
-16.69%
6 Months
-34.44%
9 Months
-45.00%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
17Sep
MIRA Pharmaceuticals submits Ketamir-2 CIPN protocol targeting Q1 2027 start
MIRA Pharmaceuticals submitted its Phase 2a Ketamir-2 protocol for CIPN to an IRB. The protocol incorporates feedback received from the U.S. Food and Drug Administration. Site initiation is targeted for the first quarter of 2027. The study aims to generate initial efficacy and dose-response data for the drug.
1mo ago
1Sep
MIRA Pharmaceuticals stock rises 17% on MIRA-55 toxicology data
MIRA Pharmaceuticals stock rose 16.87% to $0.90 on positive MIRA-55 toxicology data. Dose-range studies in rats and dogs established cross-species metrics for IND-enabling program. Global non-opioid pain market projected to grow from $45.3 billion in 2024 to $70.3 billion by 2030. Company targets FDA IND submission for MIRA-55 in first quarter of 2027.
2mo ago
20Aug
Mira expands at-home fertility monitor to English Canada
Mira launches at-home hormone tracker in English Canada after Health Canada approval. Device holds Class II Medical Device Licence and FDA registration. Company reports 300,000+ global users and 60,000+ reported pregnancies. Hormone detection accuracy claimed at up to 99.5%. Product unavailable in Quebec; available elsewhere in Canada.
2mo ago
10Jul
MIRA Pharma reports favorable MIRA-55 formulation results
MIRA Pharmaceuticals, Inc. announced positive preclinical results for its MIRA-55 oral formulation, showing favorable bioavailability and tissue distribution. The studies support the drug's continued development as a non-opioid therapy for chronic inflammatory pain.
4mo ago
25Jun
MIRA's Mira-55 shows distinct mechanism vs THC in study
MIRA Pharmaceuticals released preclinical data on June 25, 2026, showing Mira-55 reduces anxiety and pain without THC-like side effects, supporting its development for chronic inflammatory pain.
